<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665392</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593027</org_study_id>
    <secondary_id>GERCOR-ECHO-07-1</secondary_id>
    <secondary_id>2007-002116-25</secondary_id>
    <secondary_id>EU-20838</secondary_id>
    <secondary_id>MERCK-GERCOR-ECHO-07-1</secondary_id>
    <nct_id>NCT00665392</nct_id>
  </id_info>
  <brief_title>Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer</brief_title>
  <acronym>ECHO-07</acronym>
  <official_title>Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF) in Patient With Resectable Stage III-IV Squamous Cell Carcinoma of the Oropharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) together with cetuximab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II clinical trial is studying how well cetuximab given together with&#xD;
      combination chemotherapy works in treating patients with stage III or stage IV oropharynx&#xD;
      cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the complete clinical response rate at 3 months in patients with stage III&#xD;
           or IV nonmetastatic squamous cell carcinoma of the oropharynx treated with cetuximab,&#xD;
           docetaxel, cisplatin, and fluorouracil.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the rate of tumor response.&#xD;
&#xD;
        -  To determine progression-free and overall survival.&#xD;
&#xD;
        -  To determine the rate of complete pathological response.&#xD;
&#xD;
        -  To assess the tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15; docetaxel IV over 1 hour&#xD;
      and cisplatin IV over 1 hour on day 1; and fluorouracil IV continuously on days 1-5.&#xD;
      Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 2 months for 1 year and every&#xD;
      3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months</measure>
    <time_frame>at 3 months after ETPF combination</time_frame>
    <description>The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Clinical Response (cCR)</measure>
    <time_frame>at 3 months</time_frame>
    <description>Clinical complete response (cCR) is defined by:&#xD;
Disappearance of all clinical evidence of visible tumor,&#xD;
Disappearance of all palpable residual infiltration,&#xD;
Disappearance of all evidence of residual visible tumor on CT scan in pharynx and parapharyngeal space,&#xD;
Complete symmetric remobilization of the tongue and amygdala.&#xD;
Disappearance of pre-existing trismus.&#xD;
Negative control biopsy.&#xD;
The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 2-year Estimated Overall Survival (OS) Rate</measure>
    <time_frame>2 years</time_frame>
    <description>2-year OS measured survival at 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Response</measure>
    <time_frame>after surgery of the primary tumor</time_frame>
    <description>On primary tumor resected : measure of persistence or not of tumoral lesion, histological type, size and quality of the excision piece&#xD;
A pathological complete response is defined as no viable tumour cells detected on histological examination post surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 2-year Estimated Progression-free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>2-year PFS measured survival at 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Radiological Response (rCR)</measure>
    <time_frame>At 3 months after the end of 3 cycles of the ETPF combination</time_frame>
    <description>Radiological response is defined according to RECIST 1.0 criteria:&#xD;
Complete response (CR): disappearance of all target lesions&#xD;
Partial response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter,&#xD;
Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target the appearance of one or more new lesions,&#xD;
Stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers Analysis - HPV Genotyping</measure>
    <time_frame>correlative studies investigating HPV status in tumor and blood samples obtained prior to and after induction therapy were done for exploratory purposes as planned in the protocol</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab by intravenous (IV) infusion over 1-2 h on day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>75 mg/m², day 1. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75 mg/m² Day 1. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>750 mg/m² day 1 to day 5. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the oropharynx&#xD;
&#xD;
               -  Stage III (T3 or T1-2, N1-2, M0) or nonmetastatic stage IV (T4 or T1-3, N3, M0)&#xD;
                  disease&#xD;
&#xD;
               -  Resectable disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Tumor tissue available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  AST and ALT &lt; 5 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Affiliated with social security (including CMU)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cardiovascular accident (myocardial infarction, cerebral vascular accident) within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Serious and/or uncontrolled cardiac or respiratory disease (pulmonary fibrosis,&#xD;
             interstitial pneumopathy)&#xD;
&#xD;
          -  Other cancer within the past 5 years except for resected skin cancer, localized&#xD;
             cutaneous or totally resected melanoma, or resected carcinoma in situ of the cervix&#xD;
&#xD;
          -  Auditory condition precluding the use of cisplatin&#xD;
&#xD;
          -  Contraindication due to psychological, social, or geographical reasons that may impede&#xD;
             proper monitoring of treatment&#xD;
&#xD;
          -  Persons under guardianship or trusteeship, or prisoners of law&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment, including chemotherapy or radiotherapy&#xD;
&#xD;
          -  No concurrent phenytoin, live attenuated vaccines, or parenteral aminoglycosides&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Lacau Saint Guily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Tenon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Simone Veil</name>
      <address>
        <city>Montmorency</city>
        <zip>95160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT00665392</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From July 2008 to April 2013, 42 patients were enrolled. This study was conducted in France, in 9 active centers: Hospital Tenon, HEGP, Hospital Bichat, GH St Joseph Paris, Hospital Foch Suresnes, CH Lyon Sud, Hospital Delafontaine St Denis, Centre René Huguenin St Cloud et Hospital Simone Veil Montmorency.</recruitment_details>
      <pre_assignment_details>The main inclusion criteria: Previously untreated, resectable stage III (T3 or T1 - 2N1 - 2M0) to IVB (T4 or T1 -3N3M0) SCCHN of the oropharynx, measurable or evaluable disease, WHO performance status ≤ 1, adequate hematologic, renal and liver functions.&#xD;
The main exclusion criteria: uncontrolled cardiac or other disease, hearing impairment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ETPF Adminstration</title>
          <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>42 patients enrolled and 41 treated. Forty-one patients (mITT population) started induction therapy. One patient did not receive an intended treatment due to investigator decision to replace cisplatin by carboplatin and not to administer cetuximab.</population>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab</title>
          <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Grade of differentiation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Well</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor or undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor localization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Anterior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral (tonsillar area)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T-stage</title>
          <description>Classification for Oropharyngeal - T for Primary tumor TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ T1 Tumor ≤2 cm in greatest dimension T2 Tumor &gt;2 cm but not more than 4cm in greatest dimension T3 Tumor &gt;4 cm in greatest dimension or extension to lingual surface of the epiglottis T4a Moderately advanced, local disease T4b Very advanced, local disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>N-stage</title>
          <description>N for Regional lymph nodes N0 No regional lymph node metastasis N1 Metastasis in a single ipsilateral lymph node ≤3 cm in greatest dimension N2 Metastasis in a single ipsilateral lymph node &gt;3 cm but not more than 6cm in greatest dimension; or in multiple ipsilateral lymph nodes, none &gt;6cm in greatest dimension; or in bilateral or contralateral lymph nodes, none &gt;6cm in greatest dimension N3 Metastasis in a lymph node &gt;6cm in greatest dimension</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>N0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Staging at the inclusion</title>
          <description>Patient with resectable stade III (T3 or T1 - 2N1 - 2M0) to IVB (T4 or T1- 3N 3M0).&#xD;
Anatomic stage/prognostic groups at the inclusion. Stade III is the best pronostic than stade IV.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lip mobility</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trismus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance (mL/min)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 -120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albuminemia (g/L)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Life style risk factors</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tobacco</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol + Tobacco</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HPV 16 status</title>
          <description>human papillomavirus type 16 status</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG performance status</title>
          <description>The ECOG Performance Status is a method to assess the functional status of a patient.&#xD;
ECOG PS 0 : Fully active, able to carry on all pre-disease performance without restriction&#xD;
ECOG PS 1 : Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG - PS=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG - PS=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months</title>
        <description>The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
        <time_frame>at 3 months after ETPF combination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months</title>
          <description>The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor response Rate - Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - Tumor and node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Clinical Response (cCR)</title>
        <description>Clinical complete response (cCR) is defined by:&#xD;
Disappearance of all clinical evidence of visible tumor,&#xD;
Disappearance of all palpable residual infiltration,&#xD;
Disappearance of all evidence of residual visible tumor on CT scan in pharynx and parapharyngeal space,&#xD;
Complete symmetric remobilization of the tongue and amygdala.&#xD;
Disappearance of pre-existing trismus.&#xD;
Negative control biopsy.&#xD;
The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
        <time_frame>at 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Clinical Response (cCR)</title>
          <description>Clinical complete response (cCR) is defined by:&#xD;
Disappearance of all clinical evidence of visible tumor,&#xD;
Disappearance of all palpable residual infiltration,&#xD;
Disappearance of all evidence of residual visible tumor on CT scan in pharynx and parapharyngeal space,&#xD;
Complete symmetric remobilization of the tongue and amygdala.&#xD;
Disappearance of pre-existing trismus.&#xD;
Negative control biopsy.&#xD;
The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor response rate - tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - Tumor and node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The 2-year Estimated Overall Survival (OS) Rate</title>
        <description>2-year OS measured survival at 2 years from randomization.</description>
        <time_frame>2 years</time_frame>
        <population>Median OS was not achieved. The 2-year estimated rate is given.</population>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The 2-year Estimated Overall Survival (OS) Rate</title>
          <description>2-year OS measured survival at 2 years from randomization.</description>
          <population>Median OS was not achieved. The 2-year estimated rate is given.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Response</title>
        <description>On primary tumor resected : measure of persistence or not of tumoral lesion, histological type, size and quality of the excision piece&#xD;
A pathological complete response is defined as no viable tumour cells detected on histological examination post surgery.</description>
        <time_frame>after surgery of the primary tumor</time_frame>
        <population>Pathological response is evaluable in patients with tumor surgical resection only</population>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response</title>
          <description>On primary tumor resected : measure of persistence or not of tumoral lesion, histological type, size and quality of the excision piece&#xD;
A pathological complete response is defined as no viable tumour cells detected on histological examination post surgery.</description>
          <population>Pathological response is evaluable in patients with tumor surgical resection only</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The 2-year Estimated Progression-free Survival (PFS)</title>
        <description>2-year PFS measured survival at 2 years from randomization.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The 2-year Estimated Progression-free Survival (PFS)</title>
          <description>2-year PFS measured survival at 2 years from randomization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Radiological Response (rCR)</title>
        <description>Radiological response is defined according to RECIST 1.0 criteria:&#xD;
Complete response (CR): disappearance of all target lesions&#xD;
Partial response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter,&#xD;
Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target the appearance of one or more new lesions,&#xD;
Stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started</description>
        <time_frame>At 3 months after the end of 3 cycles of the ETPF combination</time_frame>
        <population>Patients in the mITT population who received ETPF</population>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>Treatment consisted of cetuximab by intravenous (IV) infusion over 1-2 h on days 1, 8, and 15 (loading dose of 400 mg/m2 on day 1, then 250 mg/m2 weekly) followed the same day by docetaxel and cisplatin both given as a&#xD;
1h IV infusion (at a 75 mg/m2 dose) and by 5-FU IV infusion on days 1-5 (at a 750 mg/m2 dose per day). Treatment was given every 3 weeks for a maximum of three cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Radiological Response (rCR)</title>
          <description>Radiological response is defined according to RECIST 1.0 criteria:&#xD;
Complete response (CR): disappearance of all target lesions&#xD;
Partial response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter,&#xD;
Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target the appearance of one or more new lesions,&#xD;
Stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started</description>
          <population>Patients in the mITT population who received ETPF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor response rate - Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor response rate - Tumor and node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Biomarkers Analysis - HPV Genotyping</title>
        <time_frame>correlative studies investigating HPV status in tumor and blood samples obtained prior to and after induction therapy were done for exploratory purposes as planned in the protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ETPF Administration</title>
            <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers Analysis - HPV Genotyping</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until 1 month after the last administration</time_frame>
      <desc>Adverse events (AE) were collected during induction treatment and follow-up visit (1 month).Toxicity evaluation was carried out according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v3.0)</desc>
      <group_list>
        <group group_id="E1">
          <title>ETPF Administration</title>
          <description>cisplatin: 75 mg/m², day 1. 3 cycles&#xD;
docetaxel: 75 mg/m² Day 1. 3 cycles&#xD;
fluorouracil: 750 mg/m² day 1 to day 5. 3 cycles&#xD;
Cetuximab: 400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile aplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection at the portacath site</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regulatory Affairs</name_or_title>
      <organization>GERCOR</organization>
      <phone>+33 (0)1 40 29 85 00</phone>
      <email>regulatory.affairs@gercor.com.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

